Loading clinical trials...
Loading clinical trials...
A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma
Conditions
Interventions
perifosine
Locations
6
Canada
Tom Baker Cancer Center - Calgary
Calgary, Alberta, Canada
Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada
Princess Margaret Hospital at University Health Network
Toronto, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
McGill University
Montreal, Quebec, Canada
Start Date
June 20, 2003
Primary Completion Date
September 14, 2004
Completion Date
December 21, 2009
Last Updated
August 4, 2023
NCT06956690
NCT05649683
NCT00003641
NCT03543969
NCT04079166
NCT05492682
Lead Sponsor
NCIC Clinical Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions